Fluoroform (CHF) Production from CFCHO Photolysis and Implications for the Decomposition of Hydrofluoroolefins and Hydrochlorofluoroolefins in the Atmosphere.

Hydrofluoroolefins (HFOs) and hydrochlorofluoroolefins (HCFOs) are the leading synthetic replacements for compounds successively banned by the Montreal Protocol and amendments. HFOs and HCFOs readily decompose in the atmosphere to form fluorinated carbonyls, including CFCHO in yields of up to 100%, which are then photolyzed. A long-standing issue, critical for the transition to safe industrial gases, is whether atmospheric decomposition of CFCHO yields any quantity of CHF (HFC-23), which is one of the most environmentally hazardous greenhouse gases.

Covered Stent Correction for Sinus Venosus Atrial Septal Defects, an Emerging Alternative to Surgical Repair: Results of an International Registry.

Background: Covered stent correction for a sinus venosus atrial septal defect (SVASD) was first performed in 2009. This innovative approach was initially viewed as experimental and was reserved for highly selected patients with unusual anatomic variants. In 2016, increasing numbers of procedures began to be performed, and in several centers, it is now offered as a standard of care option alongside surgical repair.

Nutrition Insecurity, Chronic Disease, and Dietary Habits Explain Low Perceptions of Self-Rated Health.

Self-rated health (SRH), an indicator of overall health status, has been associated with morbidity and mortality. Yet links between SRH and nutrition are lacking, especially in conjunction with other characteristics affecting SRH. Therefore, the study objective was to identify significant sociodemographic/socioeconomic, chronic disease, dietary habits, and food environment explanatory variables for perceptions of self-rated health (SRH).

Phase 2 Trial of Topical Application of the Hedgehog Inhibitor Patidegib in Patients With Gorlin Syndrome.

Background: Patients with Gorlin (basal cell nevus) syndrome (GS) have numerous phenotypic abnormalities due to over-activity of the hedgehog (HH) signaling pathway, most commonly due to a heritable mutation in the PTCH1 gene, which encodes a major inhibitor of this pathway. HH inhibitors (HHi) taken orally can reverse some of the manifestations, most prominent of which is the development of numerous cutaneous basal cell carcinomas (BCCs). In order to improve the benefit:risk ratio, we have developed a gel containing a small cyclopamine-derived molecule that can be applied topically in expectation that this mode of delivery can reduce the burden of BCCs without producing the systemic adverse effects that cause patients to stop treatment with oral HHis.